NEWS HIGHLIGHTSMedia Articles Related to Buspar (Buspirone)
How A Persons "Ranks" Their Suffering May Stop Them Seeking Help For Depression And Anxiety
Source: Anxiety / Stress News From Medical News Today [2012.05.07]
People's judgements about whether they are depressed depend on how they believe their own suffering "ranks" in relation to the suffering of friends and family and the wider world, according to a new study...
Finding That Emotion Is Reversed In Left-Handers' Brains Could Lead To New Treatment For Anxiety, Depression
Source: Anxiety / Stress News From Medical News Today [2012.05.05]
The way we use our hands may determine how emotions are organized in our brains, according to a recent study published in PLoS ONE by psychologists Geoffrey Brookshire and Daniel Casasanto of The New School for Social Research in New York. Motivation, the drive to approach or withdraw from physical and social stimuli, is a basic building block of human emotion...
Obesity, Depression/Anxiety, ADHD, Asthma Contribute To Fatigue Even After A Good Night's Sleep
Source: Depression News From Medical News Today [2012.05.03]
Children who have learning, attention and behavior problems may be suffering from excessive daytime sleepiness, even though clinical tests show them sleeping long enough at night, a new study reports...
Arthritis - Anxiety Twice As Common As Depression
Source: Anxiety / Stress News From Medical News Today [2012.04.30]
Approximately one third of adults with arthritis in the USA aged 45+ years suffer from anxiety or depression, researchers from the CDC reported in the journal Arthritis Care & Research. The authors added that the prevalence of anxiety in adults with arthritis is almost twice as high as depression, in spite of more studies focusing on the arthritis-depression link...
Anxiety Or Depression Common Among Aging Adult Americans With Arthritis
Source: Anxiety / Stress News From Medical News Today [2012.04.30]
Researchers from the Centers for Disease Control and Prevention (CDC) found that one-third of U.S. adults with arthritis, 45 years and older, report having anxiety or depression...
Published Studies Related to Buspar (Buspirone)
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. [2010.12]
OBJECTIVE: The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia. This study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial... CONCLUSIONS: The present study indicates buspirone as a potential adjunctive treatment strategy for the treatment of schizophrenia, in particular, negative symptoms. Nevertheless, results of larger controlled trials are needed before recommendation for a broad clinical application can be made. This trial is registered with the Iranian Clinical Trials Registry (IRCT138712051556N8).
Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. [2010.12]
The efficacy and side effects of buspirone compared with methylphenidate (MPH) in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0.5 mg/kg/day) and methylphenidate (0.3-1 mg/kg/day) for a 6-week double-blind clinical trial...
Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. [2010.04]
AIM: Generalized anxiety disorder (GAD) in elderly people is common, but few systematic studies regarding the best treatments have been performed. The aim of the present study was to evaluate the efficacy and safety of sertraline and buspirone in the treatment of elderly patients with GAD... CONCLUSION: Both sertraline and buspirone appear to be efficacious and well tolerated in the treatment of GAD in elderly patients. Further studies with larger sample size, evaluating the effect of medical illness, cognitive impairment, depression, and combined therapy with support and psychotherapy are needed.
A placebo-controlled trial of buspirone for the treatment of marijuana dependence. [2009.11.01]
The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing.Further study with buspirone in this population may be warranted; however, strategies to enhance study retention and improve outcome measurement should be considered in future trials.
Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers. [2009.07]
RATIONALE: The human pupil may be a suitable physiological test system for the assessment of excessive daytime sleepiness (EDS), but pupillometric assessment could be confounded by medication for comorbid hypertension and mood disorders. OBJECTIVES: We examined the profile of the 5HT-2/alpha1/H1 antagonist ketanserin, the 5HT1a agonist buspirone and the beta adrenoceptor antagonist propranolol on pupillary and other measures of arousal... CONCLUSIONS: Ketanserin but not propranolol had a fully sedative profile and may confound pupillometric assessment of EDS. Beta adrenergic receptors do not appear to participate in arousal and pupillary functions, while 5HT1a receptors reduce pupil size without affecting arousal. Pupil size may not be used unequivocally as an index of the level of alertness in the case of drug-induced changes, when drugs interfere with the central pupil control mechanism in ways that are unrelated to their effects on arousal.
Clinical Trials Related to Buspar (Buspirone)
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions [Completed]
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions [Completed]
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder [Recruiting]
The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core
features of autism in autistic children aged 2-6 years as measured by the change from
baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores
compared to placebo at 6 months.
Psychopharmacology for Cocaine Dependence - Buspirone [Not yet recruiting]
Chronic cocaine use may produce disruption of neurotransmitter functions (including
dopamine). This may in turn contribute to measurable dysfunction in important cognitive and
behavioral processes. Stimulants that enhance dopamine (DA) function may help in treating
cocaine dependence and improving behavioral function - - supporting the notion that these
processes are related. An important step is to understand the subjective, physiological, and
behavioral effects of potential medications for cocaine dependence.
DA-modulating drugs may be targets for pharmacotherapy for substance dependence, and
particularly for stimulant drugs like cocaine, which disrupt normal DA function. Buspirone
is currently the only available dopamine subtype 3 (DA3) approved for human administration,
and is thus a viable investigational compound.
This project proposes to evaluate the DA-modulating effects of buspirone on behavioral
deficiencies related to DA depletion. Accordingly, the project aims to characterize the
effects of buspirone in individuals with cocaine dependence. Employing a daily dosing
designs within an acute stimulant challenge (methylphenidate), the experiment will
characterize the subjective effects, cardiovascular effects, and behavioral effects
(attentional bias to drug cues and risky decision making). The primary hypotheses are that
buspirone will attenuate the increases in subjective drug effects ("stimulated", "like
drug") and behavioral effects (increases in attentional bias and risky decision making) that
are produced by acute methylphenidate administration.
Open-label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders [Not yet recruiting]
The main objective of this exploratory 8 week pilot study is to evaluate the safety and
efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism
spectrum disorders. The study results will be used to generate hypotheses for a larger
randomized controlled clinical trial with explicit hypotheses and sufficient statistical
power.
|
